NSE ropes in Citigroup, Morgan Stanley to handle IPO

Source: Moneycontrol Moving closer to list its shares, leading stock exchange NSE today said it has roped in four merchant bankers, including Citigroup and Morgan Stanley, to manage its upcoming initial public offering. The other joint global co-ordinators are JM Financial Institutional Securities and Kotak Mahindra Capital Company. Besides, the exchange has engaged Cyril Amarchand Mangaldas as the legal [...]

August 24th, 2016|

Venture Intelligence 2016 – AZB, Cyril Amarchand top PE, M&A tables

Source: Bar and Bench Venture Intelligence recently released its legal advisors league tables for Private Equity and M&A transactions in 2016, with AZB & Partners taking the top spot in PE deals and Cyril Amarchand Mangaldas topping the M&A tables. The league tables are updated till July 2016. PE Deals Deal Value Apart from leading in [...]

August 23rd, 2016|

A&O, CAM advise on NTPC’s first ‘green masala’ bonds

Source: Asian Legal Business Cyril Amarchand Mangaldas (CAM) has advised NTPC, India’s largest power company on its offering of “green masala” bonds, with Allen & Overy advising the lead managers. This is the first corporate masala bond, or Indian rupee-denominated bonds issued in offshore capital markets, offering to commit proceeds to “green” projects. HDFC opened [...]

August 23rd, 2016|

Khaitan, Cyril Amarchand act on Aditya Birla Nuvo-Grasim merger

Source: Bar and Bench Aditya Birla Nuvo Ltd (ABNL) will merge with Grasim Industries Ltd in a bid to unlock shareholder value and create a $9 billion (Rs 59,766 crore) enterprise. With the merger, the Aditya Birla Group decided to hive off its financial services business into a separate entity, which will be listed later. [...]

August 16th, 2016|

AZB, Cyril Amarchand on Tata Group’s sale of Urea biz to Yara Fertilizers for 2,760 crore

Source: Bar and Bench Tata Group has sold its Urea business, part of Tata Chemicals to Pune-based Yara Fertilizers India for Rs 2,670 crore ($400 million). AZB & Partners acted for Tata Group with a team led by Partner Rishi Gautam. Cyril Amarchand Mangaldas advised Yara Fertilizers with a team led by Mumbai-based corporate partners [...]

August 11th, 2016|

HDFC Life and Max Life to merge their Life Insurance Businesses

Source: Indiainfoline The Board of Directors of HDFC Standard Life Insurance Company Limited (“HDFC Life”), Max Life Insurance Company Limited (“Max Life”), Max Financial Services Limited (“Max Financial Services”) and Max India Limited (“Max India”) at their respective meetings held today, approved entering into definitive agreements for amalgamation of businesses between the entities through a [...]

August 10th, 2016|

CAM, STB, Troutman Sanders on $1.3 bln India-China pharma deal

Source: Asian Legal Business Troutman Sanders has advised China’s Shanghai Fosun Pharmaceutical Group on its agreement to buy an 86 percent stake in India’s Gland Pharma, represented by Cyril Amarchand Mangaldas and Simpson Thacher & Bartlett for up to $1.3 billion. This is the largest acquisition of an Indian company from abroad this year. According [...]

August 3rd, 2016|

Cyril Amarchand, S&R, CC act on L&T Infotech’s $184 mln IPO

Source: Asian Legal Business Cyril Amarchand Mangaldas has advised India’s Larsen & Toubro Infotech on its 12.36-billion-rupee ($184 million) initial public offering, with S&R Associates and Clifford Chance representing the lead managers . L&T Infotech, India's sixth-biggest software services exporter, is a subsidiary of engineering services provider Larsen & Toubro. The parent sold part of [...]

August 3rd, 2016|

Khaitan, CAM, 2 foreigns on record $1.3bn Gland Pharma FDI from China

Source: Legally India Shanghai Fosun Pharmaceutical (Group) Co. Ltd, the Hong Kong-listed company controlled by billionaire Guo Guangchang, will acquire India’s Gland Pharma Ltd for $1.3 billion (Rs 8,700 crore), the company announced on Thursday. According to the agreement, Fosun will acquire an approximate 86% stake in Gland, including the 36% stake held by existing [...]

August 3rd, 2016|
 

DISCLAIMER

This website has been designed only for the purposes of dissemination of basic information on Cyril Amarchand Mangaldas; information which is otherwise available on the internet, various public platforms and social media. Careful attention has been given to ensure that the information provided herein is accurate and up-to-date. However, Cyril Amarchand Mangaldas is not responsible for any reliance that a reader places on such information and shall not be liable for any loss or damage caused due to any inaccuracy in or exclusion of any information, or its interpretation thereof. Reader is advised to confirm the veracity of the same from independent and expert sources.

This website is not an attempt to advertise or solicit clients, and does not seek to create or invite any lawyer-client relationship. The links provided on this website are to facilitate access to basic information on Cyril Amarchand Mangaldas, and, to share the various thought leadership initiatives undertaken by it. The content herein or on such links should not be construed as a legal reference or legal advice. Readers are advised not to act on any information contained herein or on the links and should refer to legal counsels and experts in their respective jurisdictions for further information and to determine its impact.

Cyril Amarchand Mangaldas advises against the use of the communication platform provided on this website for exchange of any confidential, business or politically sensitive information. User is requested to use his or her judgment and exchange of any such information shall be solely at the user’s risk.

Cyril Amarchand Mangaldas uses cookies on its website to improve its usability. This helps us in providing a good user experience and to also help in improving our website. By continuing to use our website without changing your privacy settings, you agree to use our cookies.